Disease · MONDO_0005399
Comparisons in its trials83
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 83
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Apixaban vs Warfarin: Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital | 11,966 of 11,966 | 1,979 of 1,979 | 13,945 | NCT05795062 | Trial comparisons |
| Dabigatran 150 mg vs Warfarin: serious adverse events | 156 of 1,280 | 153 of 1,288 | 2,568 | NCT00680186 | Trial comparisons |
| Dabigatran 150 mg vs Warfarin: serious adverse events | 165 of 1,273 | 150 of 1,266 | 2,539 | NCT00291330 | Trial comparisons |
| Apixaban vs Dalteparin: Recurrent Venous Thromboembolism | 32 of 576 | 46 of 579 | 1,155 | NCT03045406 | Trial comparisons |
| Apixaban vs Dalteparin: deaths from any cause | 135 of 576 | 153 of 579 | 1,155 | NCT03045406 | Trial comparisons |
| Apixaban vs Dalteparin: serious adverse events | 255 of 576 | 276 of 579 | 1,155 | NCT03045406 | Trial comparisons |
| Edoxaban Group vs Dalteparin Group: Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event | 67 of 522 | 71 of 524 | 1,046 | NCT02073682 | Trial comparisons |
| Edoxaban Group vs Dalteparin Group: Number of Participants With Recurrent VTE, Major Bleed or All-Cause Death | 235 of 522 | 228 of 524 | 1,046 | NCT02073682 | Trial comparisons |
| Edoxaban Group vs Dalteparin Group: Number of Participants With Adjudicated Major Bleeding Events While on Treatment | 32 of 522 | 16 of 524 | 1,046 | NCT02073682 | Trial comparisons |
| Edoxaban Group vs Dalteparin Group: Number of Participants With Recurrent Venous Thromboembolism (VTE) During the Overall Study Period | 41 of 522 | 59 of 524 | 1,046 | NCT02073682 | Trial comparisons |
| Edoxaban Group vs Dalteparin Group: Number of Participants With Recurrent Deep Vein Thrombosis (DVT) During the Overall Study Period | 19 of 522 | 35 of 524 | 1,046 | NCT02073682 | Trial comparisons |
| Edoxaban Group vs Dalteparin Group: Number of Participants With Recurrent Non-Fatal Pulmonary Embolism (PE) During the Overall Study Period | 21 of 522 | 24 of 524 | 1,046 | NCT02073682 | Trial comparisons |
| Edoxaban Group vs Dalteparin Group: deaths from any cause | 206 of 522 | 192 of 524 | 1,046 | NCT02073682 | Trial comparisons |
| Edoxaban Group vs Dalteparin Group: Number of Participants With VTE-Related Death | 6 of 522 | 4 of 524 | 1,046 | NCT02073682 | Trial comparisons |
| Edoxaban Group vs Dalteparin Group: serious adverse events | 276 of 522 | 251 of 524 | 1,046 | NCT02073682 | Trial comparisons |
| Comparator Group vs Rivaroxaban Group: deaths from any cause | 0 of 162 | 2 of 329 | 491 | NCT02234843 | Trial comparisons |
| Comparator Group vs Rivaroxaban Group: serious adverse events | 35 of 162 | 78 of 329 | 491 | NCT02234843 | Trial comparisons |
| Therapeutic Anticoagulation vs Standard Care: All-cause Death | 4 of 228 | 18 of 237 | 465 | NCT04362085 | Trial comparisons |
| Therapeutic Anticoagulation vs Standard Care: Composite Outcome of ICU Admission or All-cause Death | 4 of 228 | 1 of 237 | 465 | NCT04362085 | Trial comparisons |
| Therapeutic Anticoagulation vs Standard Care: Composite Outcome of Mechanical Ventilation or All-cause Death | 23 of 228 | 28 of 237 | 465 | NCT04362085 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005399/comparisons